Solid Tumors

Second-generation Hsp90 inhibitor to be studied in advanced solid tumor patients

Published in Cancer Weekly, August 17th, 2004

Kosan Biosciences Incorporated (KOSN) announced the initiation of the first phase I clinical trial of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (DMAG) in cancer patients with advanced solid tumors.

DMAG is a second-generation Hsp90 inhibitor that is highly potent and water soluble and has good oral bioavailability.

Kosan's first-generation Hsp90 inhibitor includes an original drug substance 17-AAG in a DMSO and egg lecithin vehicle and a new formulation, KOS-953, both of which are being evaluated in the clinic.

The DMAG clinical trial is sponsored by the National Cancer Institute (NCI) under a Cooperative Research and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2004-08-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry